Document Detail


Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group.
MedLine Citation:
PMID:  8360134     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An open, randomized study was performed at 18 European centres to compare the efficacy, safety and tolerance of oral fluconazole with oral polyenes for the prophylaxis of fungal colonization and infection in adults at high risk of developing neutropenia. Five hundred and thirty-six hospitalized patients with malignant disease, about to receive chemotherapy, radiotherapy, or bone marrow transplantation, and who were already neutropenic or were expected to develop neutropenia were included in the study. Before therapy or transplantation, patients commenced either oral fluconazole therapy (50 mg/day as a single dose) or oral polyenes therapy (amphotericin B 2 g/day and/or nystatin 4 x 10(6) units/day in four or more divided doses), for a mean of 29.3 days and 31.3 days, respectively. After baseline clinical and mycological testing, patients were re-evaluated at least weekly during prophylaxis, at the end of prophylaxis and two to six weeks later to identify proven or suspected fungal infection and to determine rates of colonization with fungi. Fungal infection was diagnosed in 41 of 511 evaluable patients, 10 (3.9%) of 256 in the fluconazole group and 31 (12.2%) of 255 in the polyene group (P = 0.001). This total included four patients (1.6%) in the fluconazole group who developed oropharyngeal candidiasis compared with 22 (8.6%) in the polyene group (P < 0.001). Systemic infections comprised 6 (2.3%) in the fluconazole group and 9 (3.5%) in the polyene group (P = not significant), and included three Candida krusei infections in each group. Parenteral amphotericin B therapy was given empirically for persistent fevers in an additional 62 (24.2%) patients receiving fluconazole and 59 (23.1%) receiving polyenes (P = not significant). Colonization with fungi was generally similar in each treatment group, although an increased proportion of patients receiving fluconazole developed colonization of the faeces (P < 0.01). Adverse reactions, possibly related to treatment, were recorded in 15 (5.6%) of 269 patients in the fluconazole group and 14 (5.2%) of 267 in the polyene group; these necessitated discontinuation of therapy in seven patients in each group. Once-a-day fluconazole was therefore more effective than oral polyenes for the prevention of oropharyngeal fungal infection and as effective for the prevention of infections at other sites in patients with neutropenia.
Authors:
J N Philpott-Howard; J J Wade; G J Mufti; K W Brammer; G Ehninger
Related Documents :
17827354 - Comparison of artemether-lumefantrine with sulfadoxine-pyrimethamine for the treatment ...
1543674 - Treatment of cutaneous sporotrichosis with terbinafine.
7873824 - Clinical experience with short schedules of itraconazole in the treatment of tinea corp...
9250234 - Isoniazid preventive therapy in human immunodeficiency virus-infected persons. long-ter...
16299194 - Has the assessment of isolated ankle injuries altered since 1993?
10726794 - Latanoprost: experience of 2-year treatment in scandinavia.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  The Journal of antimicrobial chemotherapy     Volume:  31     ISSN:  0305-7453     ISO Abbreviation:  J. Antimicrob. Chemother.     Publication Date:  1993 Jun 
Date Detail:
Created Date:  1993-09-30     Completed Date:  1993-09-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7513617     Medline TA:  J Antimicrob Chemother     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  973-84     Citation Subset:  IM    
Affiliation:
Department of Medical Microbiology, King's College School of Medicine and Dentistry, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adolescent
Adult
Aged
Aged, 80 and over
Amphotericin B / administration & dosage,  adverse effects,  therapeutic use*
Child
Female
Fluconazole / administration & dosage,  adverse effects,  therapeutic use*
Humans
Male
Middle Aged
Mycoses / prevention & control*
Neutropenia / complications*
Nystatin / administration & dosage,  adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
1397-89-3/Amphotericin B; 1400-61-9/Nystatin; 86386-73-4/Fluconazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clarithromycin versus cefaclor for the treatment of mild-to-moderate acute bacterial bronchitis.
Next Document:  The management of infections and antibiotic therapy: a European survey.